Navigation Links
New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon

SAN DIEGO, May 22, 2007 /PRNewswire/ -- A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo. This study also demonstrated, as in previous studies, that patients treated with zolpidem did have impaired performances on these measures, as compared to placebo. The results of this double-blind, placebo-controlled trial were presented in a poster at the American Psychiatric Association 2007 Annual Meeting.

"These data are important because they indicate that ramelteon is a safe sleep medication for patients, especially older adults, concerned about being impaired in the middle of the night," said Gary Zammit, PhD, Director, Sleep Disorders Institute, New York. "Many older adults have concerns about their mobility should they get out of bed in the middle of the night for any reason, such as the need to use the bathroom or even react to an emergency. This study showed that when taking ramelteon, balance and mobility were not significantly affected."

Study Design

A total of 33 adults age 65 or older who suffered from insomnia at least three nights per week for over three months received ramelteon 8 mg, zolpidem 10 mg or placebo 30 minutes before bedtime for one night each in a single- dose, three-period crossover study. Patients were awakened two hours after they were given medication to evaluate standing balance, turning speed and stability, memory and adverse events. The primary endpoint was balance as assessed by NeuroCom EquiTest Sensory Organization Test score (SOT) two hours after dosage.

An SOT protocol objectively identifies abnormalities in patients' use of the three sensory systems that contribute to postural control: somatosensory (perception of sensory stimuli from the skin and internal organs), visual and vestibular (balance system having to do with the audi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/23/2008)... publication in July print edition of Clinical ...DIANAPOLIS, July 23 /- A Roche Diagno...N-terminal pro-B-type natriuretic peptide,(NT-proB...risk,stratification in predicting the risk of card...ted with non-steroidal anti-inflammatory drugs of,...
(Date:7/23/2008)...3 /- InCode BioPharmaceutics, Inc.,a...ced preclinical test,results demonstrating the uti...eatment of the rare chronic blood disorder paroxys...esults will be presented at the XXII,International...ber 28,2008., The only treatment currently avail...
(Date:7/22/2008).../- Nonin Medical, a leading innovator...an 20 years, has entered,the clinical testing phas...onal oxygen saturation. Today,s most common applic...ring of the regional blood oxygenation,in the brai...utcomes from an ongoing clinical study at the,Duke...
(Date:7/22/2008)... Lantus(R) and Apidra(R) Resulted in Significant, ..., Whatever the Algorithm ...ire/ -- Results from the "Adjust to,Target in Type...arbohydrate,Counting for Adjustment of Mealtime In...ican Diabetes Association,s (ADA) medical journal,...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Almost Family Announces Expansion of Revolving Credit Facility 7573 1Almost Family Announces Expansion of Revolving Credit Facility 7573 2Almost Family Announces Expansion of Revolving Credit Facility 7573 3Capital BlueCross HMO Plan is Ranked No 1 in Pennsylvania for Member Satisfaction 7571 1Capital BlueCross HMO Plan is Ranked No 1 in Pennsylvania for Member Satisfaction 7571 27 or 8 Hours of Sleep Best for Health 7569 1Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2067 1Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2067 2
...earch and Treatment of Rare but Devastating,Condit...ry University London,and the University of Leicest...ntial breakthrough in the treatment of a rare but,...dren and young,people. , In a world first, the cli...ave already treated one patient with promising,res...
...tner Forest Laboratories, Inc. Today,Announced the...cute,Ischemic Stroke) Study with the Compound Desm...N AG (Frankfurt Stock,Exchange, Prime Standard: PA...YSE: FRX) today announced topline results of,the D...y with the,compound Desmoteplase. The Phase III st...
Other Medicine Technology:World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... location for clinical trials for many pharmaceuti...s Squibb, GlaxoSmithkline, Eli Lilly are among tho...y. Currently over 226 clinical trials approved by...nd Drug Administration (FDA) are in India. Faced...
...hospital mortality is on the high during weekends.... not matching with the inflow// of the patients. T...is team from the University of Medicine and Dentis...ostis studied 231,164 patients who were admitted t...
...olysed casein proteins reduced the development of ...rom Germany. "The 3-year results of this large-sc...learly confirm the concept that the risk for [atop...thma can be reduced by nutritional intervention in...
...wn as "eSie Touch Elasticity Imaging" will be show...ropean Congress of Radiology) in Vienna//, Austria...n adjunct to regular breast ultrasound examination...ion of benign and malignant tissue. The method is ...
Other Medicine News:Health News:India Fast Become Prime Location for Clinical Trials, but Vigilance Called for 2Health News:Hydrolysed Casein Formula may Slash Eczema in Infants 2Health News:eSie Touch Elasticity Imaging, and a Promise of Avoiding Breast Biopsies 2
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: